Korro Bio, Inc. - Asset Resilience Ratio
Korro Bio, Inc. (KRRO) has an Asset Resilience Ratio of 28.47% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. For the complete balance sheet picture, see KRRO current and non-current assets.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Korro Bio, Inc.'s Asset Resilience Ratio has changed over time. Read KRRO current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Korro Bio, Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. See KRRO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $52.27 Million | 28.47% |
| Total Liquid Assets | $52.27 Million | 28.47% |
Asset Resilience Insights
- Very High Liquidity: Korro Bio, Inc. maintains exceptional liquid asset reserves at 28.47% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Korro Bio, Inc. Industry Peers by Asset Resilience Ratio
Compare Korro Bio, Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Savara Inc
NASDAQ:SVRA |
Biotechnology | 68.30% |
|
Chengdu Kanghua Biological Products
SHE:300841 |
Biotechnology | 1.19% |
|
Seegene Inc
KQ:096530 |
Biotechnology | 28.16% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Shanghai Shen Lian Biomedical Corp
SHG:688098 |
Biotechnology | 0.69% |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT |
Biotechnology | 33.20% |
|
NervGen Pharma Corp
V:NGEN |
Biotechnology | 0.25% |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089 |
Biotechnology | 3.60% |
Annual Asset Resilience Ratio for Korro Bio, Inc. (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Korro Bio, Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 46.99% | $53.33 Million | $113.51 Million | +15.85pp |
| 2024-12-31 | 31.14% | $70.45 Million | $226.24 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $221.66 Million | -- |
| 2022-12-31 | 25.65% | $18.91 Million | $73.74 Million | -1.90pp |
| 2021-12-31 | 27.55% | $51.07 Million | $185.36 Million | +19.85pp |
| 2019-12-31 | 7.70% | $17.20 Million | $223.22 Million | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more